Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Nucleic Acids and Circulating Rare Cells: Liquid Biopsy for Early Cancer Detection

Cheng-Ho Jimmy Lin's Biography

Cheng-Ho Jimmy Lin, Chief Scientific Officer, Natera

C. Jimmy Lin, MD, PhD, MHS is the Chief Scientific Officer (CSO), Oncology at Natera. He comes from a long history as a pioneer in cancer genomics. Most recently, he led the clinical genomics program at the National Cancer Institute (NCI) at the National Institutes of Health (NIH). Previously, at Johns Hopkins and Washington University in St. Louis, Dr. Lin was part of one of the first clinical genomics labs in academia and led the computational analyses of the first ever exome sequencing studies in cancer, including breast, colorectal, pancreatic, glioblastoma, medulloblastoma, and melanoma. He has published in top academic journals, such as Science, Nature, and Cell, and has been an expert in national and international media outlets, such as New York Times, Forbes, Bloomberg Businessweek, Washington Post, and the Financial Times.

Cheng-Ho Jimmy Lin Image

Personalized Circulating Tumor DNA Technology

Thursday, 29 March 2018 at 14:00

Add to Calendar ▼2018-03-29 14:00:002018-03-29 15:00:00Europe/LondonPersonalized Circulating Tumor DNA

There is great promise in using circulating tumor DNA in biofluids and other human specimen in cancer care. I will present the different technologies for ctDNA; then we will the promises and challenges on how these can be applied for different indications such as diagnosis, early detection, treatment monitoring, minimal residual disease, and patient selection.

Add to Calendar ▼2018-03-28 00:00:002018-03-29 00:00:00Europe/LondonCirculating Nucleic Acids and Circulating Rare Cells: Liquid Biopsy for Early Cancer Detection